Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.

Background: Implementation and uptake of novel and cost-effective medicines can improve patient health outcomes and healthcare efficiency. However, the uptake of new medicines into practice faces a wide range of obstacles. Earlier reviews provided insights into determinants for new medicine uptake (such as medicine, prescriber, patient, organization, and external environment factors).

High-risk individuals' perceptions of reproductive genetic testing for CDH1 mutations.

Reproductive genetic testing- PreNatal Diagnosis (PND) and Preimplantation Genetic Diagnosis (PGD)-for CDH1 mutations associated with Hereditary Diffuse Gastric Cancer (HDGC)is available in the UK. This qualitative interview study examined high-risk individuals' (n = 35) views of CDH1 reproductive genetic testing. Interviewees generally regarded reproductive genetic testing as an acceptable form of HDGC risk management.

The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC).

Individuals identified as at high risk of developing Hereditary Diffuse Gastric Cancer (HDGC) are advised to undergo prophylactic surgery - have their stomach removed - in their early twenties. Research with (older) cancer patients who undergo gastrectomy for curative reasons suggests that gastric resection has a number of physical and psychosocial sequelae. Because it is difficult to extrapolate the findings of studies of older cancer patients to younger healthy patients who are considering prophylactic total gastrectomy (PTG), the aim of this qualitative interview study was to determine the psychosocial implications of undergoing prophylactic surgery to manage genetic risk.

An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC).

Hereditary diffuse gastric cancer has an early onset and poor prognosis, therefore, individuals who carry a pathogenic (CDH1) mutation in the E-cadherin gene (CDH1) are offered endoscopic surveillance and advised to undergo prophylactic total gastrectomy (PTG) in their early to mid-twenties. Patients not ready or fit to undergo gastrectomy, or in whom the genetic testing result is unknown or ambiguous, are offered surveillance. Little is known about the factors that influence decisions to undergo or decline PTG, making it difficult to provide optimal support for those facing these decisions.

Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

Importance: E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk and spectrum in germline mutation carriers are essential for management. For families without CDH1 mutations, genetic-based risk stratification has not been possible, resulting in limited clinical options.

Client and therapist views on exercise programmes for early-mid stage Parkinson's disease and Huntington's disease.

Purpose: Physiotherapists frequently prescribe home exercise programmes for individuals with Parkinson's disease (PD) and Huntington's disease (HD); however, little is known about clients' perceptions of such programmes and any barriers that may affect participation and compliance.

Method: A qualitative design was used to capture the attitudes and experiences of people with early-mid stage HD and PD, and with physiotherapists who have experience in neurodegenerative diseases. Two focus groups were conducted for physiotherapists (n = 8); individual interviews were conducted for clients with HD and PD (n = 10).

Oves contraceptive cap: short-term acceptability, aspects of use and user satisfaction.

Objective: To assess the short-term acceptability, aspects of use and user satisfaction with the Oves cap.

Design, Setting And Subjects: A multicentre observational study, commissioned by Veos Ltd, manufacturers of the Oves cap, was carried out by the UK Family Planning and Reproductive Health Research Network in collaboration with the Institute of Population Studies, University of Exeter, Exeter, UK. Women from ten Network centres and one collaborating centre were invited to participate.